# Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

> **NCT01744626** · PHASE1 · COMPLETED · sponsor: **Celgene Corporation** · enrollment: 40 (actual)

## Conditions studied

- Leukemia Lymphocytic Chronic B-Cell

## Interventions

- **DRUG:** CC-292
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT01744626
- **Lead sponsor:** Celgene Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2016-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01744626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01744626, "Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01744626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*